Gabriel Tatarian, DO
Neurology · Philadelphia, PANPI 1164487914
Payments from drug & device makers
Across 241 payments — averaging $886.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz Pharmaceuticals, LLC$148K
- Biogen$49K
- Sanofi$10K
- TG Therapeutics, Inc.$4K
- Abbott$920
- Novartis$522
- plus $2K from 26 others
What the payments were for
- Consulting fees$15,2107%
- Speaking & faculty fees$41,57519%
- Travel & lodging$2,5791%
- Food & beverage$6,6043%
- Education$1440%
- Other$147,54069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz Pharmaceuticals, LLC | 11 | $147,599 |
| Biogen | 70 | $48,529 |
| Sanofi | 32 | $10,332 |
| TG Therapeutics, Inc. | 12 | $3,751 |
| Abbott | 13 | $920 |
| Novartis | 16 | $522 |
| AbbVie(2 entities) | 16 | $308 |
| Lilly USA, LLC | 13 | $246 |
| Genentech USA, Inc. | 6 | $192 |
| UCB, Inc. | 6 | $140 |
| Teva Pharmaceuticals USA, Inc. | 7 | $125 |
| Amgen | 4 | $102 |
| EMD Serono, Inc. | 4 | $99 |
| Eisai Inc. | 3 | $79 |
| Pfizer | 3 | $76 |
| Insightec,inc | 1 | $74 |
| Kyowa Kirin, Inc. | 2 | $59 |
| AstraZeneca(2 entities) | 2 | $58 |
| Upsher-smith Laboratories LLC | 3 | $49 |
| Argenx US, Inc. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $40 |
| Acorda Therapeutics, Inc | 2 | $40 |
| Boston Scientific | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| CSL Behring | 1 | $32 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| MDD US Operations, LLC | 1 | $17 |
| Revance Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$147,540
- TYSABRI$18,254
- Vumerity$18,169
- LEMTRADA$9,653
- BRIUMVI$3,524
- INFINITY$308
- Infinity DBS Pulse Generators$306
- TECFIDERA$243
- DISEASE STATE$124
- MAYZENT$110
How this compares
$213,652 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 108 | $1,377,722 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 64 | $724,086 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 25 | $273,113 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $252,317 |
| AubagioTeriflunomide | 12 | $109,016 |
| CopaxoneGlatiramer Acetate | 15 | $81,090 |
| AmpyraDalfampridine | 18 | $78,137 |
| Dalfampridine ErDalfampridine | 41 | $39,839 |
| Nurtec OdtRimegepant Sulfate | 30 | $38,992 |
| UbrelvyUbrogepant | 29 | $30,166 |
| QuliptaAtogepant | 13 | $13,973 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,295 |
| DilantinPhenytoin Sodium Extended | 13 | $3,739 |
| ValiumDiazepam | 13 | $3,644 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 99 | $2,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $32 | $724,08664 claims |
| PfizerOctagam, Nurtec Odt, Dilantin | $76 | $295,04769 claims |
| SanofiAubagio | $10,332 | $109,01612 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $125 | $81,09015 claims |
| Acorda Therapeutics, IncAmpyra | $40 | $78,13718 claims |
| AbbVieUbrelvy, Qulipta | $308 | $44,13942 claims |
| Upsher-smith Laboratories LLCTopiramate | $49 | $1,07857 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $18 | $70913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.